Company Overview of Octapharma AG
Octapharma AG engages in the development, production, and sale of medicines derived from human proteins in the areas of haematology, immunotherapy, and intensive care and emergency medicine. The company develops and manufactures haematology products, such as coagulation factor concentrates for patients with bleeding disorders, as well as develops commercial recombinant coagulation Factor VIII designed to reduce the immunogenic challenge in patients with haemophilia A. It also offers a portfolio of intensive care and emergency medicine comprising human plasma and protein products for treating critically ill or injured patients in intensive care and emergency settings. In addition, the company...
Founded in 1983
Key Executives for Octapharma AG
Chairman of Management Board
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc Usa
Member of Management Board and President for Octapharma Usa Inc
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2013.
Octapharma AG Key Developments
Octapharma AG Signs Supply Agreement with Ethicon
Oct 25 13
Octapharma AG has signed a long-term, strategic supply agreement with Ethicon. Under the agreement, supply of the biological components will begin after all necessary process validations are completed and regulatory approvals have been achieved.
Octapharma Receives US FDA Approval for Octaplas(R)
Jan 18 13
ProMetic Life Sciences Inc. announced that it has received confirmation from Octapharma of the regulatory approval of Octaplas(R) by the Food and Drug Administration for the US market. ProMetic's proprietary prion capture resin, PrioClear(TM), is incorporated in Octapharma's manufacturing process for its solvent/detergent treated, prion-reduced, plasma product, Octaplas(R).
Octapharma AG Reports Earnings Results for the Year Ended December 31, 2011; Provides Earnings Guidance for 2012
Apr 3 12
Octapharma AG reported earnings results for the year ended December 31, 2011. Net sales stand at EUR 732 million, which is EUR 14 million or 2% above the 2010 figure. The figures for the last months in 2011 indicate a significant improvement in profitability for 2012. Gross profit in 2011 is EUR 205 million, representing 28% of net sales and an increase of EUR 31 million compared to 2010. Operating expenses are EUR 141 million, EUR 8 million or almost 6% less than in 2010. This includes EUR 43 million investments into Research and Development. Earnings Before Interest and Tax (EBIT) can be reported at EUR 64 million. This reflects a 164% increase compared to 2010.
The promising first months of octagam(R) returning to the markets allow a positive outlook and it is expected that all key figures will further improve during 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries